Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155673 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Extension Study of Study GCS-100-CS-4002
A Phase 2 study, sponsored by La Jolla Pharmaceutical Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT02155673: Completed Phase 2 study, sponsored by La Jolla Pharmaceutical Company.
NCT02155673 is a Phase 2 study that has completed, run by La Jolla Pharmaceutical Company. The registered enrollment target is 92 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02155673, a Phase 2 study, has completed, sponsored by La Jolla Pharmaceutical Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safety and tolerability of extended dosing of GCS-100 in patients with CKD.
Primary Outcome
Evaluation of safety measures for long-term dosing including collection of adverse events in clinically significant changes in lab values
Interventions
- DRUG GCS-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
What the finished NCT02155673 record still lists
NCT02155673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (31% lower).
The record links to 0 conditions, and to 1 intervention - of which GCS-100 is the first listed.
NCT02155673 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02155673 about?
NCT02155673 is a clinical study titled "A Phase 2 Extension Study of Study GCS-100-CS-4002". The primary objective of this study is to determine the safety and tolerability of extended dosing of GCS-100 in patients with CKD.
What is the current status of trial NCT02155673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2014-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02155673?
The interventions under investigation include: GCS-100 (DRUG).
Who is sponsoring clinical trial NCT02155673?
This trial is sponsored by La Jolla Pharmaceutical Company, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02155673's enrollment target sits among peer trials
92 767th of 2000 higher than 1,230 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia